SIMI Law Group, P.C.
Recombinant adenovirus with increased safety and anticancer activities, and use thereof
The present invention relates to a recombinant adenovirus with increased in-vivo safety, tissue specificity, and anticancer activities, and a use thereof. Specifically, the recombinant adenovirus comprising: a promoter of the liver tissue-specific phosphoenolpyruvate carboxykinase (PEPCK) gene; a trans-splicing ribozyme which is operably linked to the promoter and acts on a cancer-specific gene; a therapeutic gene or a reporter gene which is linked to the 3′ exon of the ribozyme; and a serotype 35 fiber knob and a serotype 5 shaft, in which the orf4 gene is deleted from adenovirus E1, E3 and E4 orf1, shows remarkable in-vivo safety, high specificity for a target tissue, and remarkable anticancer effects, and thus can be useful for an anticancer drug or a cancer diagnostic agent as a gene delivery vector.
NATIONAL CANCER CENTER
C A G C C C C C A C C C A A C G C C C C G C C C C
C12N A61K G01N C12N C12N C12N C12N C12N A61K C12N C12N C12N A61K A61K C12Y G01N C12N C12Y C12N C12N G01N C12N C12N C12N C12N
additional inventional inventional additional additional additional inventional additional inventional additional additional additional inventional inventional additional inventional inventional inventional inventional inventional additional additional additional additional inventional
Sang Young Sang Jin In-Hoo Jin-Sook Yun-Hee Seong-Wook
Han Lee Kim Jeong Kim Lee